RARγ is a negative regulator of osteoclastogenesis

Alanna C Green, Ingrid J Poulton, Christina Vrahnas, Karl D Hausler, Carl R Walkley, Joy Y Wu, Thomas John Martin, Matthew Todd Gillespie, Roshantha A S Chandraratna, Julian Michael Warner Quinn, Natalie A Sims, Louise E Purton

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)


Vitamin A is known to influence post-natal bone content, with excess intake being associated with reduced bone mineral density and increased fracture risk. Despite this, the roles retinoids play in regulating osteoclastogenesis, particularly in vivo, remain unresolved. This study therefore aimed to determine the effect of loss of retinoic acid receptors (RAR)alpha or RARgamma on bone mass (analyzed by histomorphometry and dual-energy X-ray absorptiometry) and osteoclastogenesis in mice in vivo. RARgamma null mice had significantly less trabecular bone at 8 weeks of age compared to wildtype littermates. In contrast, no change in trabecular bone mass was detected in RARalpha null mice at this age. Further histomorphometric analysis revealed a significantly greater osteoclast surface in bones from 8-week-old RARgamma null male mice. This in vivo effect was cell lineage autonomous, and was associated with increased osteoclastogenesis in vitro from hematopoietic cells obtained from 8-week-old RARgamma null male mice. The use of highly selective agonists in RANKL-induced osteoclast differentiation of wild type mouse whole bone marrow cells and RAW264.7 cells in vitro showed a stronger inhibitory effect of RARgamma than RARalpha agonists, suggesting that RARgamma is a more potent inhibitor of osteoclastogenesis. Furthermore, NFAT activation was also more strongly inhibited by RARgamma than RARalpha agonists. While RARalpha and RARgamma antagonists did not significantly affect osteoclast numbers in vitro, larger osteoclasts were observed in cultures stimulated with the antagonists, suggesting increased osteoclast fusion. Further investigation into the effect of retinoids in vivo revealed that oral administration of 5mg/kg/day ATRA for 10 days protected against bone loss induced by granulocyte colony-stimulating factor (G-CSF) by inhibiting the pro-osteoclastogenic action of G-CSF. Collectively, our data indicates a physiological role for RARgamma as a negative regulator of osteoclastogenesis in vivo and in vitro, and reveals distinct influences of RARalpha and RARgamma in bone structure regulation.
Original languageEnglish
Pages (from-to)46 - 53
Number of pages8
JournalJournal of Steroid Biochemistry and Molecular Biology
Publication statusPublished - 2015

Cite this